Table 3.
Effect of IPTsc on anaemia during the intervention period
| Study site | Drug regime | No of children | Prevalence of anaemia (%) | PE (95 % CI) | |
|---|---|---|---|---|---|
| Clarke [24] | Bondo | SP + AQ (four-monthly) | 2604 | 6.3 | 50 (41–53) |
| Placebo | 2302 | 12.6 | – | ||
| Barger [25] | Kollé | SP + AS | 96 | 17.7 | 40 (9–61) |
| AQ + AS | 100 | 16 | 46 (17–65) | ||
| Control | 98 | 29.6 | – | ||
| Nankabirwa [27] | Tororo | DP (monthly) | 717a | 12 | 40 (29–49) |
| DP (three and five monthly) | 716a | 17 | 14 (2–23) | ||
| Placebo | 736a | 20 | – |
PE protective effect, No number, SP + AQ sulfadoxine-pyrimethamine plus amodiaquine, SP + AS sulfadoxine-pyrimethamine plus artesunate, AQ + AS amodiaquine plus artesunate, DP dihydroartemisinin-piperaquine, % percentage
aTotal tests